

RAPID ALERT

DRAP ALERT No: Nº I/S/06-25-47

CRACKDOWN AGAINST FALSIFIED / SPURIOUS DRUGS

Date: 13th June, 2025

Target Audience:

- Regulatory Field Force of DRAP and Provincial Drug Control departments.
- Healthcare Professionals
- Consumers

Problem Statement:

The Directorate of Drug Control Punjab (DDCP) has informed the Drug Regulatory Authority of Pakistan that the samples of below mentioned products have been declared '*Spurious*'. The details of reports are as under:


S#	Product Name	Batch No.	Purported Manufacturer	Remarks
1.	Klaricid Tablet 500mg Each film coated contains: Clarithromycin500mg	722269XV	M/s Abbott Laboratories (Pakistan) Ltd., Landhi, Karachi.	'Spurious' as defined under clause (i) of sub- section (z-b) of Section 3 of the Drugs Act, 1976.
2.	Terbisil Tablet 250mg Each tablet contains: Terbinafine as hydrochloride250mg	473	M/s Saffron Pharmaceuticals (Pvt.) Ltd., 19 Km, Sheikhupura Road, Faisalabad.	'Spurious' as defined under clause (i) & (ii) of sub-section (z-b) of Section 3 of the Drugs Act, 1976.
3.	Carefen Suspension 450mL Each 5mL contains: Ibuprofen100mg	CN-37	M/s Wellcare Pharmaceuticals., A/7 P.S.I.E., Sargodha	'Spurious' as defined under clause (i) of sub- section (z-b) of Section 3 of the Drugs Act, 1976.
4.	DROPHA Tablet Each film coated tablet contains: Dydrogesterone10mg	DRP-0005	M/s Himax Pharmaceutical, Plot No. 445, Korangi Industrial Area, Karachi.	'Spurious' as per Section 3(z-b) (i) of the Drugs Act, 1976.

DRAP, Islamabad

+ 92 051 9255969

Ø

gsms@dra.gov.pk



Risk Statement:

Falsified products having no active ingredient or identification of manufacturer pose a great risk to the health of patient and can cause adverse drug reactions or may lead to therapy failure that can result in fatal consequences.

Action Initiated: -

The Regulatory Field Force of DRAP and Provincial Drug Control Departments has been directed to conduct surveillance activities throughout the supply chain to confiscate the falsified products.

Advice for Healthcare Professionals: -

DRAP requests healthcare professionals to have increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by above mentioned product. Any adverse events or quality problems experienced with the use of these products should be reported to National or Provincial pharmacovigilance centers using <u>Adverse Event Reporting Form</u> or online through this <u>link</u>. Further information on reporting problems to DRAP is available on this <u>link</u>.

Advice for Consumers:

Consumers should not use these products and should contact their physician or healthcare provider(s) if they have experienced any problem related to taking or using the above mentioned products and should report the incident to the Drug Regulatory Authority of Pakistan / National Pharmacovigilance Centre. All therapeutic goods must be obtained from licensed pharmacies and other authorized/licensed retail outlets. The authenticity and condition of products should be carefully checked. Seek advice from your pharmacists or other healthcare professionals in case of any doubt.





DRAP, Islamabad

+ 92 051 9255969

A

gsms@dra.gov.pk

Ø